These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 16338022)

  • 21. Evidence of multiple hepatitis virus infections in autopsied materials of intravenous drug addicts.
    Schleicher S; Schieffer M; Jürgens S; Wehner HD; Flehmig B
    Ig Sanita Pubbl; 2005; 61(5):435-50. PubMed ID: 17214028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low replication and variability of HBV pre-core in concomitant infection with hepatitis B and hepatitis C viruses.
    De Mitri MS; Morsica G; Cassini R; Bagaglio S; Andreone P; Bianchi G; Loggi E; Bernardi M
    Arch Virol; 2007 Feb; 152(2):395-404. PubMed ID: 16953307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal model for study of human hepatitis viruses.
    Chayama K; Hayes CN; Hiraga N; Abe H; Tsuge M; Imamura M
    J Gastroenterol Hepatol; 2011 Jan; 26(1):13-8. PubMed ID: 21175788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-abundance drug resistance mutations: extending the HIV paradigm to hepatitis B virus.
    Menzo S; Vincenti D; Solmone M; Prosperi M; Bruselles A; Abbate I; Rozera G; Capobianchi MR
    J Infect Dis; 2009 Dec; 200(11):1798-9; author reply 1799-1800. PubMed ID: 19905934
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
    Soriano V; Barreiro P; Martín-Carbonero L; Castellares C; Ruiz-Sancho A; Labarga P; Ramos B; Gonzalez-Lahoz J
    J Infect Dis; 2007 Apr; 195(8):1181-3. PubMed ID: 17357055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
    Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
    Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of cccDNA function in hepatitis B virus infection.
    Levrero M; Pollicino T; Petersen J; Belloni L; Raimondo G; Dandri M
    J Hepatol; 2009 Sep; 51(3):581-92. PubMed ID: 19616338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Technique for the early detection of drug-resistant HBV DNA during antiviral therapy.
    Yeon JE
    Intervirology; 2008; 51 Suppl 1():7-10. PubMed ID: 18544942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular and virological mechanisms of HBV drug resistance.
    Locarnini S; Mason WS
    J Hepatol; 2006 Feb; 44(2):422-31. PubMed ID: 16364492
    [No Abstract]   [Full Text] [Related]  

  • 32. New insights into hepatitis B and C virus co-infection.
    Brass V; Moradpour D
    J Hepatol; 2009 Sep; 51(3):423-5. PubMed ID: 19596479
    [No Abstract]   [Full Text] [Related]  

  • 33. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment.
    Chu CJ; Lee SD
    J Gastroenterol Hepatol; 2008 Apr; 23(4):512-20. PubMed ID: 18397482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A primer on the molecular virology of hepatitis C.
    Moradpour D; Blum HE
    Liver Int; 2004 Dec; 24(6):519-25. PubMed ID: 15566499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viral hepatocarcinogenesis: from infection to cancer.
    Tan A; Yeh SH; Liu CJ; Cheung C; Chen PJ
    Liver Int; 2008 Feb; 28(2):175-88. PubMed ID: 18251977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Markers of hepatitis virus].
    Suzuki F
    Rinsho Byori; 2008 Nov; 56(11):1014-8. PubMed ID: 19086457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chronic generalized infection caused by hepatitis viruses (clinical morphological analysis)].
    Serov VV
    Klin Med (Mosk); 1997; 75(12):4-7. PubMed ID: 9503802
    [No Abstract]   [Full Text] [Related]  

  • 39. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ribavirin: is it a mutagen for hepatitis C virus?
    Perelson AS; Layden TJ
    Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.